Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 254169, 9 pages
http://dx.doi.org/10.1155/2015/254169
Clinical Study

Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome

1Department of Endocrinology and Division of Laboratory Research, University Hospital, University of Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Germany
2Institute of Medical Psychology and Behavioral Immunobiology, University Hospital, University of Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Germany
3Department of Gastroenterology and Hepatology, University Hospital, University of Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Germany

Received 28 October 2014; Revised 18 February 2015; Accepted 27 February 2015

Academic Editor: Andreas Tomaschitz

Copyright © 2015 Susanne Tan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Azziz, K. S. Woods, R. Reyna, T. J. Key, E. S. Knochenhauer, and B. O. Yildiz, “The prevalence and features of the polycystic ovary syndrome in an unselected population,” Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2745–2749, 1839. View at Publisher · View at Google Scholar
  2. B. C. J. M. Fauser, J. Chang, R. Azziz, R. Legro, D. Dewailly, and S. Franks, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS),” Human Reproduction, vol. 19, no. 1, pp. 41–47, 2004. View at Publisher · View at Google Scholar
  3. A. Dunaif, K. R. Segal, W. Futterweit, and A. Dobrjansky, “Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome,” Diabetes, vol. 38, no. 9, pp. 1165–1174, 1989. View at Publisher · View at Google Scholar · View at Scopus
  4. C. G. Solomon, F. B. Hu, A. Dunaif et al., “Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 19, pp. 2421–2426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. Shaw, C. N. B. Merz, R. Azziz et al., “Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored women's ischemia syndrome evaluation,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 4, pp. 1276–1284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Targher, E. Solagna, F. Tosi et al., “Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome,” Journal of Endocrinological Investigation, vol. 32, no. 8, pp. 695–700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Cerda, R. M. Pérez-Ayuso, A. Riquelme et al., “Nonalcoholic fatty liver disease in women with polycystic ovary syndrome,” Journal of Hepatology, vol. 47, no. 3, pp. 412–417, 2007. View at Publisher · View at Google Scholar
  8. M. Gambarin-Gelwan, S. V. Kinkhabwala, T. D. Schiano, C. Bodian, H.-C. Yeh, and W. Futterweit, “Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome,” Clinical Gastroenterology and Hepatology, vol. 5, no. 4, pp. 496–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Brzozowska, G. Ostapowicz, and M. D. Weltman, “An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 243–247, 2009. View at Publisher · View at Google Scholar
  10. T. L. Setji, N. D. Holland, L. L. Sanders, K. C. Pereira, A. M. Diehl, and A. J. Brown, “Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 5, pp. 1741–1747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Tan, L. P. Bechmann, S. Benson et al., “Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 343–348, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. A. Adams, J. F. Lymp, J. St. Sauver et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Ertle, A. Dechêne, J.-P. Sowa et al., “Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis,” International Journal of Cancer, vol. 128, no. 10, pp. 2436–2443, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Marchesini, M. Brizi, G. Blanchi et al., “Nonalcoholic fatty liver disease—a feature of the metabolic syndrome,” Diabetes, vol. 50, no. 8, pp. 1844–1850, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Pagano, G. Pacini, G. Musso et al., “Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association,” Hepatology, vol. 35, no. 2, pp. 367–372, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Bugianesi, P. Manzini, S. D'Antico et al., “Relative contribution of iron burden, HFE mutation and insulin resistance to fibrosis in nonalcoholic fatty liver,” Hepatology, vol. 39, no. 1, pp. 179–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Hossain, A. Afendy, M. Stepanova et al., “Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 7, no. 11, pp. 1224.e2–1229.e2, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Bantel, M. J. Bahr, and K. Schulze-Osthoff, “An apoptosis biomarker for prediction of nonalcoholic steatohepatitis,” Hepatology, vol. 50, no. 3, p. 991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Bantel, C. P. Strassburg, and M. P. Manns, “Autoimmune hepatitis,” Current Gastroenterology Reports, vol. 7, no. 2, pp. 81–83, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. E. Feldstein and G. J. Gores, “Apoptosis in alcoholic and nonalcoholic steatohepatitis,” Frontiers in Bioscience, vol. 10, no. 3, pp. 3093–3099, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Canbay, S. Friedman, and G. J. Gores, “Apoptosis: the nexus of liver injury and fibrosis,” Hepatology, vol. 39, no. 2, pp. 273–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Feldstein and G. J. Gores, “Steatohepatitis and apoptosis: therapeutic implications,” The American Journal of Gastroenterology, vol. 99, no. 9, pp. 1718–1719, 2004. View at Publisher · View at Google Scholar
  24. A. E. Feldstein, A. Canbay, P. Angulo et al., “Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis,” Gastroenterology, vol. 125, no. 2, pp. 437–443, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y.-C. Liu, N. N. Zein, and A. J. McCullough, “Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study,” Hepatology, vol. 50, no. 4, pp. 1072–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Wieckowska, N. N. Zein, L. M. Yerian, A. R. Lopez, A. J. McCullough, and A. E. Feldstein, “In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease,” Hepatology, vol. 44, no. 1, pp. 27–33, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Bantel, P. Ruck, M. Gregor, and K. Schulze-Osthoff, “Detection of elevated caspase activation and early apoptosis in liver diseases,” European Journal of Cell Biology, vol. 80, no. 3, pp. 230–239, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Greystoke, J. Cummings, T. Ward et al., “Optimisation of circulating biomarkers of cell death for routine clinical use,” Annals of Oncology, vol. 19, no. 5, pp. 990–995, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005–2023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Tan, S. Hahn, S. Benson et al., “Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance,” European Journal of Endocrinology, vol. 157, no. 5, pp. 669–676, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. M. E. Cleasby, N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen, and J.-M. Ye, “Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms,” Diabetes, vol. 53, no. 12, pp. 3258–3266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, and M. J. Birnbaum, “Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP,” Nature, vol. 494, no. 7436, pp. 256–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, and N. Melchionda, “Metformin in non-alcoholic steatohepatitis,” The Lancet, vol. 358, no. 9285, pp. 893–894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Uygun, A. Kadayifci, A. T. Isik et al., “Metformin in the treatment of patients with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 5, pp. 537–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Bugianesi, E. Gentilcore, R. Manini et al., “A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease,” The American Journal of Gastroenterology, vol. 100, no. 5, pp. 1082–1090, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Duseja, A. Das, R. K. Dhiman et al., “Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions,” Annals of Hepatology, vol. 6, no. 4, pp. 222–226, 2007. View at Google Scholar · View at Scopus
  37. R. Idilman, D. Mizrak, D. Corapcioglu et al., “Clinical trial: Insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 2, pp. 200–208, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Loomba, G. Lutchman, D. E. Kleiner et al., “Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis,” Alimentary Pharmacology & Therapeutics, vol. 29, no. 2, pp. 172–182, 2009. View at Publisher · View at Google Scholar
  39. A. Nar and O. Gedik, “The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease,” Acta Diabetologica, vol. 46, no. 2, pp. 113–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Nair, A. M. Diehl, M. Wiseman, G. H. Farr Jr., and R. P. Perrillo, “Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial,” Alimentary Pharmacology & Therapeutics, vol. 20, no. 1, pp. 23–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. J. W. Haukeland, Z. Konopski, H. B. Eggesbø et al., “Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 853–860, 2009. View at Publisher · View at Google Scholar
  42. W. W. Shields and W. J. Coyle, “The effect of metformin and standard therapy vs. standard therapy alone in patients with insulin resistance and non-alcoholic steatohepatitis (NASH): a pilot study,” Gastroenterology, vol. 132, no. 4, Article ID A813-A, 2007. View at Google Scholar
  43. D. Preiss, N. Sattar, L. Harborne, J. Norman, and R. Fleming, “The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome,” International Journal of Clinical Practice, vol. 62, no. 9, pp. 1337–1343, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. M. F. Gangale, L. Miele, A. Lanzone et al., “Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome,” Clinical Endocrinology, vol. 75, no. 4, pp. 520–527, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. P. Hermans, J. C. Levy, R. J. Morris, and R. C. Turner, “Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes,” Diabetologia, vol. 42, no. 6, pp. 678–687, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. M. P. Hermans, J. C. Levy, R. J. Morris, and R. C. Turner, “Comparison of tests of β-cell function across a range of glucose tolerance from normal to diabetes,” Diabetes, vol. 48, no. 9, pp. 1779–1786, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Publisher · View at Google Scholar · View at Scopus
  48. A. L. F. D. A. Salgado, L. de Carvalho, A. C. Oliveira, V. N. dos Santos, J. G. Vieira, and E. R. Parise, “Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals,” Arquivos de Gastroenterologia, vol. 47, no. 2, pp. 165–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. S. A. Harrison, D. Oliver, H. L. Arnold, S. Gogia, and B. A. Neuschwander-Tetri, “Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease,” Gut, vol. 57, no. 10, pp. 1441–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. J. B. Dixon, P. S. Bhathal, and P. E. O'Brien, “Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese,” Gastroenterology, vol. 121, no. 1, pp. 91–100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. L. P. Bechmann, G. Marquitan, C. Jochum, F. Saner, G. Gerken, and A. Canbay, “Apoptosis versus necrosis rate as a predictor in acute liver failure following acetaminophen intoxication compared with acute-on-chronic liver failure,” Liver International, vol. 28, no. 5, pp. 713–716, 2008. View at Publisher · View at Google Scholar · View at Scopus